Table 4.
Studies reporting associations of left ventricular mass and function with outcomes in CKD
| Study (Reference) | Patients (n) | Study Design | Sample | Outcomes |
|---|---|---|---|---|
| Chen et al. (60) | 285 | Cross-sectional, all diabetic | Taiwanese outpatients | Stepwise increases in LVMI and decreases in LVEF corresponded to higher CKD stages |
| Nitta et al. (61) | 1185 | Cross-sectional, 41% diabetic | Japanese outpatients with CKD stages 3–5 | Echocardiography-based LVMI correlated with eGFR (r=0.18); patients with LVH had lower GFR and more proteinuria compared with those without |
| McQuarrie et al. (62) | 49 | Cross-sectional | British outpatients with CKD stages 2–4 | Log-PCR correlated with LVMI by cMRI (r=0.52); proteinuria explained 23% of LVMI variance |
| Chen et al. (64) | 415 | Longitudinal, 53% diabetic | Taiwanese outpatients with CKD stages 3–5 | cLVH measured by echocardiography associated with progression to ESRD (aHR, 2.03 [95% CI, 1.00 to 4.10]) |
| Chen et al. (65) | 540 | Longitudinal, 50% diabetic | Taiwanese outpatients with CKD stages 3–5 | Those with higher uric acid and LVMI had higher hazard of progression to dialysis and higher odds of rapid decline in eGFR (aHR, 1.83 [95% CI, 1.01 to 3.33]; aOR, 2.23 [95% CI, 1.06 to 4.70]) |
| Park et al. (66) | 3866 MESA | Longitudinal, 11% diabetic | eGFR>60 ml/min per 1.73 m2 | During a median follow-up of 4.8 yr, each SD higher LV concentricity was associated with a 9% and 8% decline in eGFRcr and eGFRcys |
| Silberberg et al. (59) | 91 | Longitudinal | Canadian patients from single center with incident ESRD | Those with highest versus lowest quintile of LVMI at baseline experienced higher hazards of all-cause mortality and CV mortality (aHR, 2.9 [95% CI, 1.3 to 6.9] and 2.7 [95% CI, 0.9 to 8.2]) |
| Chen et al. (67) | 505 | Longitudinal, 56% diabetic | Taiwanese outpatients with CKD stages 3–5 | Every g/m2 increase in LVMI and LVEF<55% versus ≥55% were associated with increased CV events (aHR, 1.006 [95% CI, 1.002 to 1.010] and 2.01 [95% CI, 1.01 to 3.74]) |
MESA, Multi-Ethnic Study of Atherosclerosis; cMRI, cardiac magnetic resonance imaging; cLVH, concentric LVH; aHR, adjusted hazard ratio; 95% CI, confidence interval; aOR, adjusted odds ratio; eGFRcr, eGFR calculated using serum creatinine; eGFRcys, eGFR calculated using cystatin C.